CN102453726A - Construction method of human Smac gene eukaryotic expression vector pcDNA3.1-Smac - Google Patents
Construction method of human Smac gene eukaryotic expression vector pcDNA3.1-Smac Download PDFInfo
- Publication number
- CN102453726A CN102453726A CN2010105293049A CN201010529304A CN102453726A CN 102453726 A CN102453726 A CN 102453726A CN 2010105293049 A CN2010105293049 A CN 2010105293049A CN 201010529304 A CN201010529304 A CN 201010529304A CN 102453726 A CN102453726 A CN 102453726A
- Authority
- CN
- China
- Prior art keywords
- smac
- gene
- primer
- expression vector
- plasmid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013604 expression vector Substances 0.000 title claims abstract description 19
- 238000010276 construction Methods 0.000 title claims abstract description 9
- 101000871228 Homo sapiens Diablo IAP-binding mitochondrial protein Proteins 0.000 title abstract 2
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 claims abstract description 48
- 239000013612 plasmid Substances 0.000 claims abstract description 32
- 230000003321 amplification Effects 0.000 claims abstract description 24
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 24
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000012634 fragment Substances 0.000 claims abstract description 14
- 238000001962 electrophoresis Methods 0.000 claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 10
- 210000001550 testis Anatomy 0.000 claims abstract description 9
- 102000004190 Enzymes Human genes 0.000 claims description 26
- 108090000790 Enzymes Proteins 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 238000012360 testing method Methods 0.000 claims description 18
- 238000012408 PCR amplification Methods 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- 108010005054 Deoxyribonuclease BamHI Proteins 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000011144 upstream manufacturing Methods 0.000 claims description 7
- 108090000364 Ligases Proteins 0.000 claims description 6
- 102000003960 Ligases Human genes 0.000 claims description 6
- 230000004087 circulation Effects 0.000 claims description 6
- 108091008146 restriction endonucleases Proteins 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 15
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 abstract description 12
- 201000005202 lung cancer Diseases 0.000 abstract description 12
- 208000020816 lung neoplasm Diseases 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 10
- 230000029087 digestion Effects 0.000 abstract description 7
- 230000014509 gene expression Effects 0.000 abstract description 7
- 238000003757 reverse transcription PCR Methods 0.000 abstract description 7
- 238000000246 agarose gel electrophoresis Methods 0.000 abstract description 4
- 230000006907 apoptotic process Effects 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000009466 transformation Effects 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 description 33
- 241000894006 Bacteria Species 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 25
- 229940088598 enzyme Drugs 0.000 description 23
- 238000000137 annealing Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 229910001868 water Inorganic materials 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- 230000001954 sterilising effect Effects 0.000 description 13
- 238000004659 sterilization and disinfection Methods 0.000 description 13
- 239000003292 glue Substances 0.000 description 12
- 239000002585 base Substances 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000013461 design Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 229910001425 magnesium ion Inorganic materials 0.000 description 9
- 238000001179 sorption measurement Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 7
- 229960005542 ethidium bromide Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 239000000539 dimer Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 3
- 101710156605 Diablo homolog, mitochondrial Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 229920000297 Rayon Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960003311 ampicillin trihydrate Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241001206171 Stomoxys omega Species 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 231100000652 hormesis Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000009871 tenuigenin Substances 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a construction method of human Smac gene eukaryotic expression vector pcDNA3.1-Smac, which adopts reverse transcription polymerase chain reaction (RT-PCR) technology to amplify Smac full-length gene fragments from human normal testis tissues, carries out BamHI and HindIII double digestion on the Smac gene fragments, recovers the digested target gene after agarose gel electrophoresis, prepares hollow plasmid pcDNA3.1 for transformation and amplification plasmid, extracts the plasmid, uses BamHI and HindIII double digestion on the hollow plasmid pcDNA3.1, carries out electrophoresis and recovers the digested products, and is connected with the digested target gene Smac to construct recombinant eukaryotic expression vector pcDNA3.1-Smac. After the expression vector obtained by the method is successfully sequenced, the expression vector is transfected into lung cancer A549 cells, the expression of the Smac gene in the transfected lung cancer A549 cells is verified, and a foundation is laid for further researching the apoptosis promotion effect of the Smac gene on the lung cancer cells.
Description
Technical field
The present invention relates to the construction process of a kind of people's Smac gene eukaryotic expression vector pcDNA3.1-Smac.
Background technology
Lung cancer occupies first of global malignant tumour sickness rate, the mortality ratio.In China, lung cancer has replaced liver cancer to become the topmost cause of death of malignant tumour, occupies 22.7% of malignant tumour death, and M & M is also rising year by year.At present, about 80% patients with lung cancer has missed best surgical engine meeting when going to a doctor, and adopts conventional chemotherapeutics treatment can not effectively control the incidence and development of lung cancer, therefore, is necessary to explore new gene target spot and effectively treats lung cancer, to improve the prognosis of patients with lung cancer.Be accompanied by developing rapidly of molecular biosciences medical technology, cancer come from the unusual viewpoint of apoptosis conduction path reach common understanding, the gene therapy method that produces therefrom becomes one of important means of treatment cancer day by day.
In recent years discover: Smac (the second mitochondrial-derivedactivator of caspase) gene is through one of important controlling gene of plastosome approach cell death inducing.It is higher at a plurality of normal tissue expressions such as human body testis, heart, liver, spleen, kidney, ovary and prostate glands.And in cancer of the stomach, lung cancer, colorectal carcinoma, ovarian cancer, prostate cancer, rhabdosarcoma, the expression in the malignant tumor tissues such as leiomyosarcoma is all lower, points out it possibly become a kind of suppressor gene of new malignant tumour.Therefore, this gene has important researching value.
Mitochondrial protein Smac (second mitochondria-derived activator ofcaspase) claim again DIABLO (direct IAP binding protein with low PI) be 2000 by Wang
[1]And Verhagen
[2]A kind of albumen of finding simultaneously.In the research of cervical cancer, find that it under the apoptotic signal hormesis, is discharged into tenuigenin from plastosome, and combine with IAP, suppress its anti-apoptosis activity, promote the cervical cancer cell effect of apoptosis thereby produce.In order to study the apoptosis-promoting effect of Smac gene pairs lung carcinoma cell, at first need study the expression of Smac gene in lung carcinoma cell, just need a kind of construction process of Smac gene eukaryotic expression vector this moment.
Reference:
[1]Du?C,Fang?M,Li?Y,et.al.Smac,a?mitochondrial?proteinthat?promotes?cytochrome?c-dependent?caspase?activation?byeliminating?IAP?inhibition[J].Cell?2000,102(1):33-42.
[2]Verhagen?AM,Ekert?PG,Pakusch?M,et?al.Identfiicationof?DIABLO,amammalian?p?rotein?that?promotes?apoptosis?bybinding?to?and?antagonizing?IAP?proteins[J].Cell?2000,102(1):43-53.
Summary of the invention
The invention discloses the method for a kind of people's of structure Smac gene eukaryotic expression vector pcDNA3.1-Smac; The expression vector transfection that will obtain through present method is to lung cancer A549 cell; The expression in the lung cancer A549 cell after transfection of checking Smac gene is for the apoptosis-promoting effect of further studying Smac gene pairs lung carcinoma cell lays the foundation.
The present invention realizes through following technical scheme:
The construction process of a kind of people's Smac gene eukaryotic expression vector pcDNA3.1-Smac is characterized in that, may further comprise the steps:
(1) from the operation of patients with prostate cancer castration, obtains the normal testis tissue, adopt the TRIzol method from people's normal testis tissue, to extract total RNA;
(2) get the RNA that 0.1 μ g step (1) makes, become cDNA,, carry out pcr amplification Smac gene, behind the amplified production electrophoresis, reclaim the purpose fragment with the high-fidelity enzyme as template with rt test kit rt;
(3) with BamH I, HindIII respectively enzyme cut the target gene fragment that pcDNA3.1 (-) and step (2) make, dna gel reclaims test kit and extracts endonuclease bamhi;
(4) endonuclease bamhi that step (3) is made connects through ligase enzyme, obtains Smac gene eukaryotic expression vector pcDNA3.1-Smac;
(5) preparation competent escherichia coli cell, the carrier that step (4) is made transforms, increases and extracts plasmid.
During said step (2) amplification Smac gene, reaction system is 50 μ L:5 * buffer10 μ L, 2.5mM dNTP 4 μ L, each 1 μ L of upstream and downstream primer, 5U/ μ L, high-fidelity enzyme 0.5 μ L, ddH
2O 31.5 μ L; Template DNA 2 μ L (<200ng), amplification condition: 98 ℃ of 10s, 55 ℃ of 15s; 72 ℃ of 1min; 35 circulations, said upstream primer sequence is: 5 '-CGGGATCCCACAATGGCGGCTCTGA-3 ', the downstream primer sequence is: 5 '-CCCAAGCTTGGCCCTCAATCCTCACGC-3 '.
In the said step (3), add BamHI, HindIII respectively at primer 5 ' end, its restriction enzyme site is positioned at primer underscore part: upstream primer: 5 '-CG
GGATCCCACAATGGCGGCTCTGA-3 ', downstream primer: 5 '-CCC
AAGCTTGGCCCTCAATCCTCACGC-3 '.
Description of drawings:
Fig. 1 is the agarose gel electrophoresis figure of Smac gene RT-PCR amplified production, and M is DNAmarker, and 1 is the Smac pcr amplification product.Smac Gene RT-PCR amplification is the template reverse transcription with total RNA, carries out pcr amplification with the upstream and downstream primer of Smac gene, and amplified production obtains the band of 746bp through the agarose gel electrophoresis analysis, and is consistent with the intended purposes clip size.
Fig. 2 is the agarose gel electrophoresis figure after recombinant plasmid pcDNA3.1-Smac enzyme is cut; M is DNA marker; 1 singly cuts the pcDNA3.1-Smac plasmid for BamH I, and 2 are BamH I, the two pcDNA3.1-Smac plasmids of cutting of HindIII, and 3 singly cut the pcDNA3.1-Smac plasmid for HindIII.Recombinant plasmid pcDNA3.1-Smac 2 bar segment occur behind BamH I, HindIII double digestion, about 750bp and 6000bp, and the endonuclease bamhi size conforms to desired value.
Fig. 3 is Smac gene sequencing figure as a result.
Fig. 4 is Smac gene comparison result figure, and the Smac gene order that BLAST comparison result and GenBank announce is in full accord.
Embodiment
Below in conjunction with specific embodiment the present invention is further described, these embodiment only be used to the present invention is described and be not used in the restriction scope of the present invention.The experimental technique of unreceipted actual conditions in the following example, usually according to the material normal condition, the condition that for example Gene RT-PCR increases or test kit is advised according to manufacturer is used.
One, experiment material:
1, main agents
(1) RT-PCR related reagent
Trizol American I nvitrogen
Rt test kit Japan TaKaRa
High-fidelity PCR test kit Japan TaKaRa
Agarose Spain biowest
Hundred Tykes, ethidium bromide (EB) Beijing
Glue reclaims test kit Japan TaKaRa
BamHI and HindIII restriction endonuclease Japan TaKaRa
Solution1 ligase enzyme Japan TaKaRa
(2) plasmid amplification related reagent
PcDNA3.1 (-) American I nvitrogen
Preserve in intestinal bacteria TOP10 laboratory
Peptone U.S. Gibco
Agar powder U.S. Gibco
Yeast extract U.S. Gibco
Sky, plasmid little extraction reagent kit Beijing root
Remove the little extraction reagent kit of intracellular toxin plasmid U.S. Omega Biotek
(3) cell cultures and transfection related reagent
The A549 Cell Lab is preserved
1640 substratum Hyclone
Foetal calf serum U.S. Gibco
Calf serum U.S. Gibco
Trypsinase U.S. Sartorius
Liposome lipofectamine2000 American I nvitrogen
DMSO Shanghai is general to fly
2, key instrument
(1) laboratory provides equipment
258 of microwave oven U.S.A
Water-bath Japan Nolan company 3751
Electric mixer Japan Nichiryo
The German SIMENS of cryogenic refrigerator (20 ℃~4 ℃)
Accurate micro-adjustable pipette Japan Nichiryo
Electronic balance plum Teller-Tuo benefit instrument (Shanghai) company
Inverted microscope Olympus BH-2
Table model high speed centrifuge Beijing Medical Centrifugal Machine Factory
Constant Temp. Oven Tianjin Tai Site instrument company
Electrothermostat Tianjin Tai Site instrument company
PCR electrophoresis apparatus U.S. BioRad
The table model high speed centrifuge Shanghai medical apparatus and instruments factory of making a leapleap forward
Refrigerated centrifuge U.S. Bekman
Bacteriological incubator U.S. Thermo
Cell cultures Bechtop Suzhou purifies
Microbial culture worktable Suzhou purifies
Microscope Japan Nikon
Gel analysis system U.S. BioRad
Constant temperature microbial culture shaking table Shanghai medical analytical instrument factory
The Tissue Culture Flask laboratory
The spirit lamp laboratory
(2) buy equipment by oneself
Filter net and the rod (disposable) of milling,
EP manages (200 μ l, 1500 μ l)
---30 minutes dresses of high temperature and high pressure steam sterilization box is subsequent use after the DEPC water treatment
Big-and-middle lancet head is some
---30 minutes dresses of high temperature and high pressure steam sterilization box is subsequent use after the DEPC water treatment
Erlenmeyer flask, petridish, spreader---30 minutes dresses of high temperature and high pressure steam sterilization box is subsequent use
Frozen pipe, blood counting chamber, 6 orifice plates, 9 orifice plates
One of marker pen is some with the information record
(3) experimental liquid preparation
A, DEPC water
DEPC 1ml, distilled water 1000ml, shaking table shake and spend the night, high temperature high pressure process in the bottle of packing into.
B, RPMI-1640 (1000ml)
One bag RPMI-1640 powder (1000ml), NaHCO
31.2g, be dissolved in the 1000ml pure water, the limpid nothing deposition of magnetic agitation to liquid.Filtration sterilization and packing are kept at 4 ℃ of refrigerators.
C, 0.25% pancreatin (1000ml)
0.25g pancreatin fully is dissolved in 100ml PBS liquid, bar magnet stirs 0.5h, filtration sterilization, and-20 ℃ of packing are preserved.
D, Hank ' s balanced salt damping fluid (1000ml)
CaCl20.14g, KCI0.4g, KH2P040.06g, MgCl26H2O 0.1g adds deionized water and is settled to 1000ml, autoclaving, 4 ℃ of preservations.
E, phosphate buffered saline buffer (PBS, 10x, 10 (X) ml)
1 bag PBS powder (1000ml specification) is dissolved in the 1000ml pure water, and the limpid nothing of magnetic agitation to liquid deposition divides to be filled in the 250ml vial, and autoclave sterilization can be preserved a week down for 4 ℃, the frequent autoclave sterilization of need.
F、5×TBE(1000ml)
Tris alkali 54g, boric acid 27.5g, 0.5M EDTA20ml adds deionized water constant volume 1000ml, preserves to normal temperature, and dilution is 10 times during use.
G, sepharose (1%)
Agarose 0.5g, 1 * TBE 50ml, microwave oven high-temperature digestion 1min adds EB 2.5 μ l after being cooled to 50-60 ℃, imports the glue plate, inserts comb.
H, sepharose (2%)
I、1M?CaCl
2(20ml)
CaCl21.08g, pure water 100ml, the limpid nothing deposition of magnetic agitation to liquid is used the filter filtration sterilization, is kept at-20 ℃ of refrigerators.
J, LB (Luria-Bertain) liquid nutrient medium (100ml)
Sodium-chlor 1g, peptone 1g, yeast extract 0.5g adds pure water to 1L, and branch is filled to the 250ml vial or shakes in the bacterium bottle, and autoclave sterilization is stored in 4 ℃ of refrigerators.
K, LB (Luria-Bertain) solid medium (1000ml)
Sodium-chlor 1g, peptone 1g, yeast extract 0.5g, agar powder 1.6g adds pure water to 1L, and branch is filled to the 250ml vial or shakes in the bacterium bottle, and autoclave sterilization is stored in 4 ℃ of refrigerators or bed board.
Two, experimental procedure:
1, from the operation of patients with prostate cancer castration, obtains the normal testis tissue, adopt the TRIzol method, from people's normal testis tissue, extract total RNA.
(1) 50mg is organized and cuts in taking-up from liquid nitrogen, adds 1ml Trizol liquid and grinds.
(2) the lapping liquid room temperature was placed 5 minutes, added the 0.2ml chloroform then, covered tight centrifuge tube, acutely swayed centrifuge tube 15 seconds with hand.
(3) get the upper strata water in a new centrifuge tube, add the 0.5ml Virahol, room temperature was placed 10 minutes, centrifugal 10 minutes of 12000g.
(4) abandoning supernatant adds 1ml 75% ethanol, vortex mixing, centrifugal 5 minutes of 4 ℃ of following 7500g.
(5) careful abandoning supernatant, room temperature or vacuum-drying 5-10 minute then, add the water that 50 μ l do not have RNase, inhale with the rifle head and beat several times, place for 55~60 ℃ and made the RNA dissolving in 10 minutes.
2, with rt test kit rt RNA, carry out pcr amplification Smac gene, behind the amplified production electrophoresis, reclaim the purpose fragment with the high-fidelity enzyme.
(1) with Takara rt test kit reverse transcription reaction;
Reverse transcription reaction system such as following table:
The reverse transcription reaction condition is: 37 ℃ of 15min, 85 ℃ of 5sec
(2) increase with takara high-fidelity enzyme PCR test kit;
PCR reaction system such as following table:
The condition of pcr amplification Smac full length sequence and confidential reference items β-actin: 98 ℃ of 30sec, 55 ℃ of 30sec, 72 ℃ of 1min, 35 circulations.
Measure PCR degree of purity of production and concentration.
(3) electrophoresis and glue reclaim;
A, encapsulating:
A) take by weighing the 0.9g agarose and add 1 * TAE damping fluid 60ml, in microwave oven, heat 1min;
B) be cooled to 50-60 ℃, add ethidium bromide (EB) 3 μ l to final concentration be 0.5 μ g/ml;
C) solution is imported in the glue groove of oiling comb, room temperature is placed 20-30min, and comb is extracted in adhesive curing;
D) glue is moved into electrophoresis chamber, add the paramount plastic emitting face 1-2mm of 1 * TAE, connect power supply, the point sample hole is a negative pole.
B, application of sample and electrophoresis:
A) add 1 μ l, 6 * sample-loading buffer in the 5 μ l DNA samples, behind the mixing, add in the sample well with micropipet;
B) 100v voltage stabilizing electrophoresis 40min.
C, reclaim test kit with Takara glue and carry out glue and reclaim:
A) under uv lamp, excise the sepharose that contains target DNA and put into 1.5mlEp pipe, (reduce volume as far as possible, avoid being exposed under the uv lamp for a long time);
B) weighing blob of viscose weight is with 1mg=1 μ l volume calculated;
C) the DE-1Buffer solution of 3 gel volumes of adding in blob of viscose.(1.5% glue adds 4 volumes, and 2% glue adds 5 volumes);
D) behind the uniform mixing 75 ℃ the heating 6-10min, and be interrupted the concussion blob of viscose is fully melted;
E) the DR-2Buffer solution of adding 1/2DR-1Buffer volume, uniform mixing;
F) mixed solution is transferred among the Spin Column that is placed in Collection Tube, 12, the centrifugal 1min of 000rpm abandons filtrating;
G) the Rinse A with 500 μ l adds among the Spin Column, and 12, the centrifugal 30sec of 000rpm abandons filtrating;
H) the Rinse B with 700 μ l adds among the Spin Column, and 12, the centrifugal 30sec of 000rpm abandons filtrating;
I) repetitive operation step h);
J) Spin Column is placed on the centrifuge tube of new 1.5ml, adds sterile purified water or the Elution Buffer of 25 μ l in the central authorities of Spin Column film, room temperature leaves standstill 1min.(60 preheatings help to improve elution efficiency);
K) 12, the centrifugal 1min eluted dna of 000rpm.
(4) survey DNA concentration and reclaim the purpose fragment.
3, with BamH I, HindIII respectively enzyme cut the target gene fragment that pcDNA3.1 empty plasmid and step 2 make, dna gel reclaims test kit and extracts endonuclease bamhi.
(1) the PCR design of primers is with synthetic;
Smac gene complete sequence is looked into the DB from the Genbank of NCBI.
1 acttccggcg?tgtgcgtctg?gcgtccgcgc?gctgcacaatggcggctctg?aagagttggc
61 tgtcgcgcag?cgtaacttca?ttcttcaggt?acagacagtgtttgtgtgtt?cctgttgtgg
121 ctaactttaa?gaagcggtgt?ttctcagaat?tgataagaccatggcacaaa?actgtgacga
181 ttggctttgg?agtaaccctg?tgtgcggttc?ctattgcacagaaatcagag?cctcattccc
241 ttagtagtga?agcattgatg?aggagagcag?tgtctttggtaacagatagc?acctctacct
301 ttctctctca?gaccacatat?gcgttgattg?aagctattactgaatatact?aaggctgttt
361 ataccttaac?ttctctttac?cgacaatata?caagtttacttgggaaaatg?aattcagagg
421 aggaagatga?agtgtggcag?gtgatcatag?gagccagagctgagatgact?tcaaaacacc
481 aagagtactt?gaagctggaa?accacttgga?tgactgcagttggtctttca?gagatggcag
541 cagaagctgc?atatcaaact?ggcgcagatc?aggcctctataaccgccagg?aatcacattc
601 agctggtgaa?actgcaggtg?gaagaggtgc?accagctctcccggaaagca?gaaaccaagc
661 tggcagaagc?acagatagaa?gagctccgtc?agaaaacacaggaggaaggg?gaggagc?ggg
721 ctgagtcgga?gcaggaggcc?tacctgcgtg?aggattgagggcctgagcac?actgccctgt
781 ctccccactc?agtggggaaa?gcaggggcag?atgccaccctgcccagggtt?ggcatgactg
841 tctgtgcacc?gagaagaggc?ggcagatcct?gccctggccaatcaggcgag?acgcctttgt
901 gagctgtgag?tgcctcctgt?ggtctcaggc?ttgcgctggacctggttctt?agcccttggg
961 cactgcaccc?tgtttaacat?ttcaccccac?tctgtacagctgctcttacc?catttttttt
1021 acctcacacc?caaagcattt?tgcctacctg?ggtcagagagaggagtcctt?tttgtcatgc
1081 ccttaagttc?agcaactgtt?taacctgttt?tcagtcttatttacgtcgtc?aaaaatgatt
1141 tagtacttgt?tccctctgtt?gggatgccag?ttgtggcagggggaggggaa?cctgtccagt
1201 ttgtacgatt?tctttgtatg?tatttctgat?gtgttctctgatctgccccc?actgtcctgt
1261 gaggacagct?gaggccaagg?agtgaaaaac?ctattactactaagagaagg?ggtgcagagt
1321 gtttacctgg?tgctctcaac?aggacttaac?atcaacaggacttaacacag?gcctcttgtt
1381 ccttcctttc?tttccgtttc?tctattgtat?ccaaaggagaagagtgtaag?attttgtttg
1441 catctgaaag?agaaaatgcg?tctctcctgg?ggtcctaaaaaaaaaaaaaa?aaaaaaaa
According to the Smac sequences Design PCR primer of being found, all primer sequences are synthetic by Shanghai Shen Gong company.
BamHI G^GATCC CCTAG^G
HindIII A^AGCTT TTCGA^A
Smac-P1 5-CGGGATCCCACAATGGCGGCTCTGA-3
Smac-P2 5-CCCAAGCTTGGCCCTCAATCCTCACGC-3
H-actin-p1?5-ATCGTGCGTGACATTAAGGAGAAG-3
H-actin-p2?5-AGGAAGGAAGGCTGGAAGAGT-3
Through blast comparison (http://www.ncbi.nlm.nih.gov/BLAST/), can not there be the non-specific amplification of approximate base number in checking, and is as shown in Figure 7.
(2) amplification of pcDNA3.1 and plasmid extract;
The preparation of A, competent escherichia coli cell:
A) intestinal bacteria TOP10 is coated in dull and stereotyped going up and cultivates, select independent circular mono-clonal bacterium colony, be inoculated in the 5mlLB liquid nutrient medium, 37 ℃ of shaking tables shake and spend the night;
B) draw 0.5ml bacterium liquid and be incorporated in the 50mlLB substratum, 37 ℃ of shaking culture 2h, this moment, bacterium was in logarithmic phase;
C) thalline is moved to the precooling centrifuge tube, place 10min on ice.Under 4 ℃ of conditions, reclaim sedimentary bacterium behind the centrifugal 10min of 800rpm;
D) abandon most supernatant, add 0.1mol/L CaCI2 solution 5ml piping and druming mixing deposition, place 30min on ice.4 ℃ with the centrifugal 10min recovery of 4000rpm cell;
E) abandon clean nutrient solution, add the glycerine of 2ml ice precooling, CaCI2 mixture (0.3ml glycerine+1.7ml 0.05mol/L CaCI2);
F) resuspended thalline.Divide to be filled to the 1.5mlEp pipe, every pipe 200 μ l place-80 ℃ and can preserve half a year.
B, empty plasmid pcDNA3.1 (-) transformed competence colibacillus cell:
A) get 200 μ l competent cells under the aseptic condition, add pDNA3.1 (-) DNA 2 μ l, rotate mixing gently, ice bath 30min (content is no more than 50ng, and volume is no more than 10 μ l, makes when linking of 10 μ l);
B) 42 ℃ of water-bath thermal shocking 90s place 5min on ice rapidly behind the thermal shock;
C) add 1mlLB substratum (not containing Amp), 37 ℃ of constant temperature jolt 45-60min behind the mixing, make bacterium the restore normal growth state and the resistant gene of expression plasmid;
D) 2, the centrifugal 5min of 000rpm abandons supernatant 1ml;
E) get 100 μ l after above-mentioned bacterium liquid is shaken up, evenly coat on the screen plate of Amp (final concentration that the Ampicillin Trihydrate adds LB is 50 μ g/ml, and promptly the Amp of 50 μ l 0.1g/ml adds among the LB of 100ml);
F) forehand face is upwards placed half a hour, treats bacterium fully by after the substratum absorption, and the inversion petridish was cultivated 16-24 hour for 37 ℃;
G) feminine gender is set, positive control (negative control: replace plasmid with zero(ppm) water; Positive control: dull and stereotyped) with not containing antibiotic LB;
H) get the mono-clonal bacterium with the rifle choicest, squeeze in the Erlenmeyer flask of the 50ml LB liquid nutrient medium that contains Amp.Bottleneck is pine slightly, and shaking culture is spent the night;
I) frozen bacterium liquid: 850 μ l bacterium liquid+150 μ l glycerine.
C, from step B bacterium liquid, extract plasmid, use day little extraction reagent kit of root plasmid:
A) column equilibration: the CP3 adsorption column is put into collection tube, and Xiang Zhuzhong adds 500 μ l balance liquid BL, and 12, centrifugal 1 minute of 000rpm outwells the waste liquid in the collection tube, adsorption column is relay reclaim in the collector;
B) get the bacterium liquid of 1-5ml incubated overnight, add centrifuge tube, 12, centrifugal 1 minute of 000rpm, sucking-off supernatant as far as possible;
C) in the centrifuge tube that leaves bacterial sediment, add 250 μ l solution P1, make its thorough mixing with pipettor suspension bacterial precipitation;
D) in centrifuge tube, add 250 μ l solution P2, gentleness spins upside down and makes the abundant cracking of thalline for 6-8 time.Do not want concuss, in order to avoid interrupt DNA, the time was difficult for above 5 minutes;
E) in centrifuge tube, add 350 μ l solution P3, produce white flocks.Gentleness spins upside down 6-8 time immediately, and abundant mixing is in order to avoid localized precipitation.12, centrifugal 10 minutes of 000rpm makes to be deposited in the formation of pipe bottom;
F) supernatant that will go up step collection is transferred among the adsorption column CP3, not the sucking-off deposition.Be inserted in collection tube, 12, the centrifugal 30-60 of 000rpm second outwell the waste liquid in the collection tube, CP3 puts into collection tube with adsorption column;
G) in adsorption column, add 600 μ l rinsing liquid PW, 12, the centrifugal 30-60 of 000rpm second outwell the waste liquid in the collection tube, adsorption column is put into collection tube;
H) repeating step g);
I) 2, centrifugal 2 minutes of 000rpm uncaps and placed several minutes, thoroughly rinsing liquid residual in the adsorption column is removed;
J) adsorption column CP3 is placed a clean centrifuge tube, to the middle part of adsorption film Dropwise 5 0-100 μ l elution buffer EB, room temperature was placed 2 minutes, and 12, centrifugal 1 minute of 000rpm collects plasmid solution in the centrifuge tube;
K) behind the extraction plasmid, survey its concentration.
(3) enzyme of empty plasmid pcDNA3.1 and goal gene Smac is cut;
A, the Smac gene after glue reclaimed, with BamHI, Hi ndIII double digestion:
Endonuclease reaction system such as following table;
Add reagent | Volume |
The PCR product | 25μl |
10×K?Buffer | 4μl |
BamHI | 2μl |
HindIII | 2μl |
Sterilization ddH2O | 7μl |
Total | 40μl |
37 ℃ of endonuclease reaction 3h (or spending the night), 60 ℃ of heating 15min make enzyme denaturation.
B, with empty plasmid pcDNA3.1, with BamHI, HindIII double digestion:
1 μ g plasmid adds 1 μ l enzyme and calculates endonuclease reaction system such as following table;
Add reagent | Volume |
Plasmid | 20μl |
10×K?Buffer | 4μl |
BamHI | 2μl |
HindIII | 2μl |
Sterilization ddH2O | 12μl |
Total | 40μl |
37 ℃ of endonuclease reaction 3h (or spending the night), 60 ℃ of heating 15min make enzyme denaturation.
(4) empty plasmid pcDNA3.1 and goal gene Smac endonuclease bamhi purifying;
Record one 1% sepharose, 80v voltage 50min, electrophoresis enzyme cut back PCR product.Uv lamp downcuts the little gel that contains the purpose band of trying one's best down, reclaims test kit with Takara glue and reclaims purifying.
4, ligase enzyme section makes up and obtains Smac gene eukaryotic expression vector pcDNA3.1-Smac.
Reclaim test kit with dna gel and reclaim purified pcr product, ligation system such as following table:
Add reagent | Volume |
Smac purifying fragment | 3μl |
PcDNA3.1 | 1μl |
Solution?I | 5μl |
Sterilization DD H2O | 1μl |
Total | 10μl |
16 ℃ of ligation 5h obtain Smac gene eukaryotic expression vector pcDNA3.1-Smac, and ligase enzyme is that Solution I or T4 ligase enzyme all can.
5, the amplification of carrier for expression of eukaryon pcDNA3.1-Smac and extraction.
(1) pcDNA3.1-Smac plasmid transformation escherichia coli TOP10 competent cell;
A) get 200 μ l competent cells under the aseptic condition, add pcDNA3.1-Smac DNA 10 μ l, rotate mixing gently, ice bath 30mi n;
B) 42 ℃ of water-bath thermal shocking 90s place 5min on ice rapidly behind the thermal shock;
C) add 1mlLB substratum (not containing Amp), 37 ℃ of constant temperature jolt 45-60min behind the mixing, make bacterium the restore normal growth state and the resistant gene of expression plasmid;
D) 2, the centrifugal 5min of 000rpm abandons supernatant 1ml;
E) get 100 μ l after above-mentioned bacterium liquid is shaken up, evenly coat on the screen plate of Amp (final concentration that the Ampicillin Trihydrate adds LB is 50 μ g/ml, and promptly the Amp of 50 μ l 0.1g/ml adds among the LB of 100ml);
F) forehand face is upwards placed half a hour, treats bacterium fully by after the substratum absorption, and the inversion petridish was cultivated 16-24 hour for 37 ℃;
G) feminine gender is set, positive control (negative control: replace plasmid with zero(ppm) water; Positive control: dull and stereotyped) with not containing antibiotic LB;
H) get a plurality of mono-clonal bacteriums with the rifle choicest, squeeze into respectively in the Erlenmeyer flask of 50ml LB liquid nutrient medium of a plurality of Amp of containing, bottleneck is pine slightly, and shaking culture is spent the night;
I) the frozen bacterium liquid of taking a sample respectively: 850 μ l bacterium liquid+150 μ l glycerine;
J) the bacterium liquid with different mono-clonal microbial culture send order-checking, preserves the frozen bacterium liquid of successful connection.
(2) from bacterium liquid, extract plasmid pcDNA3.1-Smac (omega removes the little extraction reagent kit of intracellular toxin plasmid);
A) above-mentioned bacterium liquid 10-15ml is packed in the 15ml centrifuge tube, centrifugal 10 minutes of 4000 * g is with precipitum under the room temperature;
B) pour out substratum, in deposition, add 500 μ l Solution/RNaseA liquid, bacterium is suspended fully with pipettor;
C) suspension moves to the 2ml centrifuge tube, adds 500 μ lSolution, puts upside down mixing gently 10-15 time;
D) add 250 μ l ice bath BufferN3, gentleness turns upside down centrifuge tube for several times, forms white precipitate;
E)>centrifugal 10 minutes of 12,000 * g room temperature;
F) supernatant is poured in the new 1.5ml centrifuge tube, added the ETR blue solution of 0.1 times of volume, put upside down test tube for several times, ice bath 10 minutes;
G) above-mentioned lysate is 42 ℃, and is 5 minutes, muddy again.Centrifugal 3 minutes of 12000 * g, ETR solution will be in test tube bottom layering;
H) supernatant is moved to another new 2ml test tube, add the absolute ethyl alcohol of 1/2 volume, put upside down 6-7 time gently, room temperature was placed 1-2 minute;
I) get a clean HiBind Mini columns and be contained on the collection tube, suct clearly 700 μ l to post, room temperature 10000 centrifugal 1 minute;
J) abandon filtrating, filter remaining supernatant, centrifugal;
K) abandon filtrating, add 500 μ l HB Buffer, centrifugal 1 minute of 10,000 * g removes albumen;
L) abandon filtrating, add 700 μ l DNA Wash Buffer (to use alcohol dilution), centrifugal 1 minute of room temperature 10,000 * g abandons filtrating;
M) repeat 1);
N) room temperature centrifugal>the centrifugal void column of 13,000 * g 2 minutes, remove ethanol;
O) pillar is put in the new 1.5Ep pipe, adds 80-100 μ l Elution Buffer.Room temperature left standstill 2 minutes.>13, centrifugal 1 minute of 000 * g can get 70-85%DNA.
But the pcDNA3.1-Smac direct transfection cell that obtain this moment.
Among the present invention, primer design is followed following principle:
1, primer length is 15-30bp, and is commonly used for about 20bp.Sufficiently long primer has guaranteed that sequence is unique, and reduces with other fragment bonded possibilities in the sequence.But length is long, such as greater than 24 bases but and do not mean that specificity is higher.Long sequence is hybridized with mismatch sometimes, thereby has reduced the specificity of primer, and long sequence annealed is slower, and goal gene amplification output is reduced.
2, primer amplification zone, routine is advisable with 200-500bp, and specified conditions can increase down and grow to the fragment of 10kb.
3, avoid between primer inside and primer, having complementary sequence as far as possible, reduce joint efficiency in order to avoid primer self combines with template.
4, selecting GC content is 40% to 60%, too high or too lowly all is unfavorable for combining of primer and DNA.A, T, G, four best stochastic distribution of base of C avoid purine or pyrimidine bunchiness more than 5 to arrange as far as possible.
5, design intermediate zone 5 ' end is the primer of C or G.Primer is increased with the stability of aim sequence hybridization and primer.
6, avoid the pairing of 3 ' terminal bases to make a mistake.Because template combines with 3 ' terminal nucleosides and extends along this direction amplification.
7, avoid 3 ' end to be rich in GC.Need guarantee during design of primers 3 A or T at 5 nucleosides at least significant end.
8, avoid 3 ' end the complementary sequence of primer to occur, otherwise might form primer dimer, thereby suppress pcr amplification.
The concentration of every primer is given birth to needed result with lower primer volume production and get final product between 10~100pmol to 0.1~1umol, may cause mispairing and produces non-specific amplification when primer concentration is higher, and can increase the chance of primer dimer formation.
Sometimes, primer 5 ' end can add the non-existent sequence of script on some aim sequences, such as promotor, and restriction site etc., this does not influence specificity of primer and combines with template.Need to detect the inside secondary structure and the primer complementarity of full sequence, but when calculating the Tm value, can not comprise these sequences.Understand under the infull situation at sequence information,, can design degenerate primer as only knowing aminoacid sequence.Various different possibly base mixing of certain occurrence of amino acid are about to encode.Can use table through reference password number, increase primer specificity.Will not annex the base design at 3 ' end at primer, make a mistake in the site because the combination of 3 ' terminal last several bases may make amplification.And to reduce merger property as far as possible, use preference with the base that adapts to different biological sequences.In addition, note primer concentration, because the primer in many merger mixtures is not exclusively to the goal gene template, so need to use higher primer concentration (1 μ M is to 3 μ M) assurance annealing normally to carry out.
Among the present invention; Pcr amplification is divided into sex change-annealing-three steps of extension, adopts three temperature spot methods to accomplish PCR:1. usually and unwinds 90~95 ℃ of double-stranded DNA sex change, 2. is cooled to 40~60 ℃ of annealing rapidly; Primer is attached on the corresponding site of target sequence; 3. be rapidly heated to 70~75 ℃, through the catalysis of Taq archaeal dna polymerase, primer strand is pressed the base complementrity pairing along template and is extended.Sometimes adopting two temperature spot method pcr amplification length is the shorter target gene of 100~300bp, and wherein, 94 ℃ of denaturation temperatures are constant, will anneal can unite two into one with elongating temperature, and about about 65 ℃, this moment, Taq DNA enzyme still had greater activity.
1, denaturation temperature and time: if denaturation temperature is low excessively, can causes and unwind not exclusively that this is one of main reason that causes the PCR failure.Common 93 ℃~94 ℃, the template DNA sex change was unwind in 1 minute, also can be lower than 93 ℃ of time expands.But can not use excessive temperature, because too high temperature can make the activity of enzyme be affected.If can not make the complete sex change of template DNA, will cause the pcr amplification failure.
2, annealing temperature and time: annealing temperature also is one, and to influence PCR specific than important factor.Because template DNA is complicated more more than primer, temperature is quickly cooled to 40 ℃~60 ℃ after sex change, and collision bonded probability combines height a lot of than the collision between the template complementary strand between primer and the template, thereby is easy to make primer and template to combine.Annealing temperature and time, depend on several factors: comprise the length of target motif row, the based composition of primer, length, concentration etc.Tm value and annealing temperature can be calculated through following formula:
Tm value (melting temperature(Tm))=4 (G+C)+2 (A+T)
Renaturation temperature=Tm value-(5~10 ℃)
Such as: account for the primer of 20 half the Nucleotide for G+C content, the starting point of right annealing temperature can be 55 ℃.
Higher renaturation temperature can reduce nonspecific combination the between primer and template, but must in Tm value allowed band, select, and makes the specificity of PCR reaction be improved.Be combined into the conventional annealing time fully between 30-60 primer second and the template.Two primers should have proximate Tm value, more are prone to obtain optimum.When differing, the Tm of two primers surpasses 5 ℃, if use lower annealing temperature in circulation is initial, to make mistakes.Can carry out 5 circulations earlier,, carry out remaining circulation according to the annealing temperature of low Tm design then according to the annealing temperature of higher Tm.Like this, under comparatively tight condition, can obtain the purpose template amplification preferably.
Formula only provides the Tm value of an estimation, and annealing temperature is a starting point that experiment is groped.In carrying out for the first time the target gene PCR experiment, can carry out the pcr amplification of annealing temperature gradient.Minimum annealing temperature is Tm-5 ℃ of estimation, with 2 ℃ be incremental change, progressively improve annealing temperature, general 5-6 Grad gets final product.
3, the temperature commonly used of the extension of elongating temperature and time: PCR reaction is 72 ℃, is typically chosen between 70~75 ℃ to get final product.It is slow excessively that elongating temperature is crossed low extension, and the too high primer that is unfavorable for of temperature combines with template.The BA of Taq archaeal dna polymerase: 55 ℃, 24 Nucleotide/S/ enzyme molecule; 70 ℃ of 60 Nucleotide/S/ enzyme molecules; 70~80 ℃ of 150 Nucleotide/S/ enzyme molecules; When being higher than 90 ℃, DNA is synthetic almost can not to carry out.According to the length of the amplified fragments decision PCR extension time, generally extend time 1min and can increase 1Kb, can the increase fragment of 3~4kb of 3~4min, the amplification 10-15min long segment about 10Kb that can increase with interior dna fragmentation.The concentration of template is low excessively, needs to prolong proliferation time, but extends overlong time, the non-specific amplification band can occur, thereby influence the PCR reaction result.
Among the present invention, concentration of reactants will be noted the following aspects:
1, enzyme and concentration thereof: the Taq archaeal dna polymerase in two kinds of sources is arranged at present, and a kind of genetically engineered enzyme is the colibacillus synthetic, and another kind is that natural enzyme purifies from the living bacillus of hot water.The concentration of enzyme is suitable, and concentration is crossed low then synthetic product amount and reduced, and too highly can cause non-specific amplification again.The PCR reaction that general catalyzed reaction volume is 100ul needs enzyme amount 2.5U approximately.
2, the quality of dNTP and concentration: quality and the concentration of pcr amplification efficient and dNTP are closely related; When dNTP solution uses; Should be made into high density with 1M NaOH or 1M Tris earlier, the damping fluid with HCl is adjusted to 7.0~7.5 with its PH again, is stored in-20 ℃ of refrigerators after the packing in a small amount.The dNTP powder is particulate state and is prone to prolonged preservation, but also can sex change lose BA as preservation is improper.The volumetric molar concentration of 4 kinds of dNTP in the PCR reaction will equate that the meeting higher or on the low side of any concentration causes mispairing, and total dNTP is about 50~200umol/L, and mistake participated in when excessive concentration can promote to extend, and crosses the low output that then can cause and reduces.
3, the concentration of primer: primer concentration is 0.2-1 μ mol/L in the general PCR reaction system, and PCR product amount is basic identical in this scope.Primer concentration is too high can to promote the primer misguidance, causes non-specific amplification, also can increase primer dimer and form; When primer concentration is lower than 0.2 μ mol/L, PCR output can descend.Non-specific amplification and primer dimer can be used as the substrate of PCR reaction again, with target sequence competitor dna polysaccharase and dNTP substrate, thereby target sequence amplification amount are reduced.Can promptly confirm primer concentration through measuring OD260 at the OD value of 260nm.
4, Mg2+ concentration: Mg2+ influences the activity of the archaeal dna polymerase of PCR, and primer annealing can remarkable influence output and specificity.In general PCR reaction, Mg2+ concentration is that 0.5~2.5mmol/L is advisable.Mg2+ concentration is crossed the low activity of Taq archaeal dna polymerase that can make and is reduced, and reduces reaction product.Excessive concentration can increase output, reduces atopic, non-specific amplification occurs, reduces fidelity.DNTP and template combine with mg ion, have reduced the amount of the needed free mg ion of enzymic activity.To all different with template, the typical PCR initial concentration that still comprises 200 μ M dNTP is 1.5mM to best magnesium ion concentration for different primers.If there is EDTA in the solution, living has other inner complexs or dna profiling in the primer storage liquid, can disturb Mg2+ effective concentration, needs this moment Mg2+ to improve consumption.
The present invention adopts RT-PCR amplification Smac gene, and makes up recombinant eukaryon expression vector pcDNA3.1-Smac through collecting the human body normal testis tissue that 1 routine patients with prostate cancer castration operation is excised.In building process; During design primer amplification Smac full length gene; Need to insert before the initiator codon respectively two restriction enzyme sites and protection base and after the terminator codon; To note simultaneously two restriction enzyme sites front and back orders should with plasmid enzyme restriction site sequence consensus, insert empty carrier to guarantee Smac gene forward.Simultaneously, during the long PCR primer of design product, be difficult to avoid forming primer dimer or the inner hairpin structure of primer, need improve the formation that the Tm value reduce primer dimer when annealing or hairpin structure this moment through the proper extension primer.In addition; The used carrier for expression of eukaryon pcDNA3.1 of the present invention (-) is initial transcribing under human cytomegalic inclusion disease virus promotor (CMV) control; Contain the polyclone restriction enzyme site, translate enhanser, BGH Transcription Termination and critical elements such as polyA tailing signal, ammonia benzyl and Xin Meisu opposing gene, be a carrier that can in mammalian cell, efficiently express and be easy to screen.
The gene table
< 110>Fu Jianfang is coated with sunshine and pays the chrysanthemum virtue
< 120>gene order of anti-vibrio alginolyticus idiotype monoclonal antibodies variable region
<160>2
<210>vh\vl
<211>123\113
<212>DNA;
< 213>artificial sequence
<220>
<221>intron
<222>(1)...(371)\(1)...(339)
<400>vh
1?CG?GCC?GAG?GTG?AAG
15?CTG?AAG?GAG?TCT?GGG?GCT?GAG?CTG?GTA?AGG?CCT?GGG?ACT?TCA?GTG
60?AAG?GTG?TCC?TGC?AAG?GCT?TCT?GGA?TAC?GCC?TTT?ACT?AAT?TAC?TTG
--------------CDR1------------
105?ATA?GAG?TGG?GTA?AAG?CAG?AGG?CCT?GGA?CAG?GGC?CTT?GAG?TGG?ATT
-----
150?GGA?GTG?ATT?AAT?CCT?GGA?AGT?GGT?GGT?ACT?AAC?TAC?AAT?GAG?AAG
------------------------CD2---------------------------
195?TTC?AAG?GGC?AAG?GCA?ACA?CTG?ACT?GCA?GAC?AAA?TCC?TCC?AGC?ACT
-----------
240?GCC?TAC?ATG?CAG?CTC?AGC?AGC?CTG?ACA?TCT?GAT?GAC?TCT?GCG?GTC
285?TAT?TTC?TGT?GCA?AGA?GGG?CGG?TTC?CCC?CAT?TAC?TAT?GCT?ATG?GAC
------------------CDR3-----------------
330?TAC?TGG?GGT?CAA?GGA?ACC?TCA?GTC?ACC?GTG?TCG?ACA?GGT?GGA?371
<400>vl
1?GAC?ATC?CAG
10?ATG?ACA?CAG?ACT?CCA?CTC?TCC?CTG?CCT?GTC?AGT?CTT?GGA?GAT?CAA
55?GCC?TCC?ATC?TCT?TGC?GGA?TCT?AGT?CAG?AGC?CTT?GTA?CAC?AGT?AAT
-------------------------CDR1---------
100?GGA?AAC?ACC?TAT?TTA?CAT?TGG?TAC?CTG?CAG?AAG?CCA?GGC?CAG?TCT
---------------------
145?CCA?AAG?CTC?CTG?ATC?TAC?AAA?GTT?TCC?AAC?CGA?TTT?TCT?GGG?GTC
-------------CDR2---------
190?CCA?GAC?AGG?TTC?AGT?GGC?AGT?GGA?TCA?GGG?ACA?GAT?TTC?ACA?CTC
235?AAG?ATC?AGC?AGA?GTG?GAG?GCT?GAG?GAT?CTG?GGA?GTT?TAT?TTC?TGC
280?TCT?CAA?AGT?ACA?CAT?GTT?CCG?CTC?ACG?TTC?GGT?GCT?GGG?ACC?AAG
---------------CDR3---------------
325?CTG?GAG?CTG?AAA?CGT?339
Claims (3)
1. the construction process of a people Smac gene eukaryotic expression vector pcDNA3.1-Smac is characterized in that, may further comprise the steps:
(1) from the operation of patients with prostate cancer castration, obtains the normal testis tissue, adopt the TRIzol method from people's normal testis tissue, to extract total RNA;
(2) get the RNA that 0.1 μ g step (1) makes, become cDNA,, carry out pcr amplification Smac gene, behind the amplified production electrophoresis, reclaim the purpose fragment with the high-fidelity enzyme as template with rt test kit rt;
(3) with BamH I, HindIII respectively enzyme cut the target gene fragment that pcDNA3.1 (-) and step (2) make, dna gel reclaims test kit and extracts endonuclease bamhi;
(4) endonuclease bamhi that step (3) is made connects through ligase enzyme, obtains Smac gene eukaryotic expression vector pcDNA3.1-Smac;
(5) preparation competent escherichia coli cell, the carrier that step (4) is made transforms, increases and extracts plasmid.
2. the construction process of a kind of people's according to claim 1 Smac gene eukaryotic expression vector pcDNA3.1-Smac; It is characterized in that: during step (2) amplification Smac gene, reaction system is 50 μ L:5 * buffer10 μ L, 2.5mM dNTP 4 μ L; Each 1 μ L of upstream and downstream primer; 5U/ μ L, high-fidelity enzyme 0.5 μ L, ddH
2O 31.5 μ L; Template DNA 2 μ L (<200ng), amplification condition: 98 ℃ of 10s, 55 ℃ of 15s; 72 ℃ of 1min; 35 circulations, said upstream primer sequence is: 5 '-CGGGATCCCACAATGGCGGCTCTGA-3 ', the downstream primer sequence is: 5 '-CCCAAGCTTGGCCCTCAATCCTCACGC-3 '.
3. the construction process of a kind of people's according to claim 1 Smac gene eukaryotic expression vector pcDNA3.1-Smac; It is characterized in that: in the step (3); Add BamHI, HindIII respectively at primer 5 ' end, its restriction enzyme site is positioned at primer underscore part: upstream primer: 5 '-CG
GGATCCCACAATGGCGGCTCTGA-3 ', downstream primer: 5 '-CCC
AAGCTTGGCCCTCAATCCTCACGC-3 '.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105293049A CN102453726A (en) | 2010-11-01 | 2010-11-01 | Construction method of human Smac gene eukaryotic expression vector pcDNA3.1-Smac |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105293049A CN102453726A (en) | 2010-11-01 | 2010-11-01 | Construction method of human Smac gene eukaryotic expression vector pcDNA3.1-Smac |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102453726A true CN102453726A (en) | 2012-05-16 |
Family
ID=46037423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010105293049A Pending CN102453726A (en) | 2010-11-01 | 2010-11-01 | Construction method of human Smac gene eukaryotic expression vector pcDNA3.1-Smac |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102453726A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103484544A (en) * | 2013-09-17 | 2014-01-01 | 遵义医学院 | Method for detecting miRNA promoter activity |
CN117646031A (en) * | 2023-08-16 | 2024-03-05 | 南京鼓楼医院 | pcDNA3.1 (+) -HOXA1 eukaryotic expression vector, construction method and application thereof |
-
2010
- 2010-11-01 CN CN2010105293049A patent/CN102453726A/en active Pending
Non-Patent Citations (3)
Title |
---|
《中华放射医学与防护杂志》 20061031 赵宝锋 等 smac 基因的克隆及过表达对宫颈癌HeLa细胞gamma射线敏感性的影响 材料与方法部分 1-3 第26卷, 第5期 * |
赵宝锋 等: "smac 基因的克隆及过表达对宫颈癌HeLa细胞γ射线敏感性的影响", 《中华放射医学与防护杂志》 * |
郭彩霞 等: "全长型人Smac基因真核表达载体构建及表达", 《中国公共卫生》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103484544A (en) * | 2013-09-17 | 2014-01-01 | 遵义医学院 | Method for detecting miRNA promoter activity |
CN117646031A (en) * | 2023-08-16 | 2024-03-05 | 南京鼓楼医院 | pcDNA3.1 (+) -HOXA1 eukaryotic expression vector, construction method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4307775B2 (en) | Use of CSF-1 inhibitors | |
CN107124889A (en) | Artificial nucleic acid molecule | |
CN106399306A (en) | sgRNA and gene vector for inhibiting bladder cancer by targeting human lncRNA-UCA1 and application of sgRNA | |
Li et al. | Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome | |
CN111205361A (en) | Interleukin 21 protein (IL21) mutants and their applications | |
Cabeza-Arvelaiz et al. | LAPSER1: a novel candidate tumor suppressor gene from 10q24. 3 | |
CN102453726A (en) | Construction method of human Smac gene eukaryotic expression vector pcDNA3.1-Smac | |
CN117701532B (en) | gRNA for KRAS-G12D gene editing, molecular system containing same and application | |
CN110551722B (en) | Nucleic acid compound and preparation method and application thereof | |
CN110317878B (en) | Long-chain non-coding RNA for diagnosis and treatment monitoring of bladder cancer and application thereof | |
CN105779576B (en) | Application of human TNFRSF12A gene and related medicine thereof | |
CN109134611B (en) | A polypeptide that specifically binds to EGFR and inhibits EGF-promoted tumor cell proliferation | |
Tsai et al. | Expression of platelet-derived growth factor and its receptors by two pre-B acute lymphocytic leukemia cell lines | |
CN113717252B (en) | CD44 antagonistic polypeptide and derivative and application thereof | |
KR20240033228A (en) | Treatment of MST1-related diseases and disorders | |
CN111228292B (en) | Application of human TPT1/TCTP gene in preparation of antitumor drugs | |
Tang et al. | Cooperative inhibitory effects of antisense oligonucleotide of cell adhesion molecules and cimetidine on cancer cell adhesion | |
CN103555750B (en) | Construction method and application of human hysteromyoma 14-3-3 gamma high expression vector | |
CN101831461B (en) | Human small RNA-148a expression vector and use thereof | |
Hu et al. | Purification of a Pd20–TNFα fusion protein that prevents liver metastasis of gastric cancer | |
CN113248619A (en) | Double-targeting chimeric antigen receptor, coding gene and recombinant expression vector | |
Guo et al. | HA117 gene increased the multidrug resistance of K562 cells in vitro: an investigation to the function of a novel gene related to drug resistance | |
CN103571838A (en) | Micro-RNA used for regulating expression of B7-H3 gene | |
CN101200715A (en) | Human CD40L expression system and method for making same | |
AU2002312081B2 (en) | WNV core protein/capsid interacting protein and uses of the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120516 |